Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating reiterated by analysts at Mizuho in a research report issued on Wednesday. They presently have a $37.00 price target on the stock. Mizuho’s target price suggests a potential downside of 2.43% from the stock’s current price.

Several other equities research analysts also recently weighed in on MYL. Cowen and Company reissued a “hold” rating and set a $30.00 price target (down previously from $43.00) on shares of Mylan N.V. in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 price target on shares of Mylan N.V. and gave the company a “hold” rating in a research report on Wednesday, August 9th. Wells Fargo & Company set a $30.00 price target on shares of Mylan N.V. and gave the company a “hold” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada reissued a “sector perform” rating and set a $32.00 price target (down previously from $33.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $45.00 price target (down previously from $50.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $42.04.

Mylan N.V. (NASDAQ:MYL) opened at 37.92 on Wednesday. The stock has a 50 day moving average price of $31.86 and a 200-day moving average price of $36.48. The stock has a market cap of $20.34 billion, a P/E ratio of 30.65 and a beta of 1.30. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. Mylan N.V. also was the target of some unusual options trading activity on Wednesday. Investors acquired 10,562 put options on the company. This is an increase of approximately 461% compared to the average daily volume of 1,883 put options.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. Mylan N.V.’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the business earned $1.16 EPS. On average, equities analysts anticipate that Mylan N.V. will post $4.52 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/mylan-n-v-myl-rating-reiterated-by-mizuho/1611265.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global X Management Co. LLC lifted its stake in shares of Mylan N.V. by 91.6% during the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares in the last quarter. TLP Group LLC purchased a new position in shares of Mylan N.V. during the 1st quarter valued at $200,000. Doliver Capital Advisors LP purchased a new position in shares of Mylan N.V. during the 2nd quarter valued at $201,000. Eagle Global Advisors LLC purchased a new position in shares of Mylan N.V. during the 2nd quarter valued at $205,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in shares of Mylan N.V. during the 2nd quarter valued at $210,000. Institutional investors own 71.97% of the company’s stock.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.